Skip to main content Accessibility help
×
Home
Hostname: page-component-684bc48f8b-vgwqb Total loading time: 0.397 Render date: 2021-04-10T11:16:45.091Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

The rise and fall of the atypical antipsychotics

Published online by Cambridge University Press:  02 January 2018

Tim Kendall
Affiliation:
National Collaborating Centre for Mental Health, Royal College of Psychiatrists' Research Unit, 4th Floor, Standon House, 21 Mansell Street, London E1 8AA, UK. Email: tim.kendall@cru.rcpsych.ac.uk
Corresponding
Rights & Permissions[Opens in a new window]

Summary

The antipsychotics brought hope and optimism to people with schizophrenia and to those who care for them. There have been successive classes of antipsychotics used by the pharmaceutical industry to persuade doctors and patients that ‘new’ is better. Evidence is growing that the primary purpose of these fabricated classes is for marketing. It is time we stopped using these expensive labels – they are all just antipsychotics.

Type
Editorials
Copyright
Copyright © Royal College of Psychiatrists, 2011 

In this Journal, Girgis et al Reference Girgis, Phillips, Li, Li, Jiang and Wu1 report the results of a 9-year follow-up of a randomised controlled trial of the first ‘typical’ antipsychotic, chlorpromazine, compared with the first prototypical ‘atypical’, clozapine, in 160 people with treatment-naive, first-episode schizophrenia in China. Believing that the atypicals were more efficacious, had fewer side-effects and may even be ‘neuroprotective’, decreasing the long-term deterioration and negative symptoms often associated with schizophrenia, the authors hypothesised 10 years ago that patients randomised to clozapine would have better long-term outcomes than those randomised to chlorpromazine. The short answer is that there is not much of a difference.

Although clozapine may be better tolerated, there were no differences on primary outcome measures, including time to remission, time spent in remission and symptom severity, by 12 months and at 9 years’ follow-up. Reference Girgis, Phillips, Li, Li, Jiang and Wu1 Girgis et al clear a little of the fog generated by the mass of cleverly constructed trials and selectively published Reference Spielmans and Parry2 data supporting a marketing strategy of ‘smoke and mirrors’ Reference Leucht, Kissling and Davis3 that has underpinned our collective misunderstanding about the so-called atypical antipsychotics.

With the exception of clozapine for treatment-resistant schizophrenia, 4 the atypicals, as a group of antipsychotics, are no more efficacious for schizophrenia than the typicals, whether it is chronic or acute, for first or subsequent episodes, for the acute episode or for promoting recovery 4 and, now, from the Girgis et al trial, probably in the longer-term when used from the first episode onwards. No doubt there are differences between different individual antipsychotic drugs in terms of potency, efficacy and side-effects. But these differences have been overplayed and systematically linked to a class effect of the atypicals.

The story of the atypical antipsychotics is a tale of the triumph of profit over patient benefit, of marketing over ethics. For the past 15–20 years, most psychiatrists, like Girgis et al, have held the view that the atypical antipsychotics are more efficacious and safe than the older typicals. Where is the evidence that there is a unifying chemical structure for, or a clinically important difference in, the efficacy or effectiveness of ‘neuroleptics’, ‘major tranquillisers’, and ‘conventional’, ‘typical’, ‘atypical’, ‘first-generation’ and ‘second-generation’ antipsychotics? Is the ever changing terminology part of the fog generated by pharmaceutical companies to increase profits by the simple equation that ‘new is better’? Perhaps the importance of these ‘classes’ lies not in their scientific or medical usefulness, but as an example of some of the most effective marketing in pharmaceutical history – a history worth examining briefly.

The birth of the antipsychotics

The first controlled trial of chlorpromazine took place on a ‘back’ ward in Birmingham in 1954. Reference Elkes and Elkes5 Chlorpromazine was given to 27 chronically overactive patients with psychosis (three described as ‘senile’) and alternated with placebo for varying periods to ascertain the drug’s impact on behaviour over 22 weeks. Each patient acted as their own control, and they and the ward staff, who assessed patient behaviour on a daily basis, were masked as to whether the patient was receiving placebo or chlorpromazine. The best effects were seen if the drug was given at 150 mg for 6 weeks continuously; switching to placebo in those who had responded produced deterioration. Importantly, the content of the patients’ psychotic experiences was unaltered. The drug calmed about two-thirds of the patients, at least to some degree; a third were behaviourally unchanged; and both positive effects and side-effects were dose-related. Interestingly, during the 2-week placebo period, at the start all patients improved, but this improvement disappeared for those who did not take chlorpromazine in the subsequent period.

The obvious interest the staff took in the patients during the trial and the notes of optimism in this 1954 study are a testament to the importance of hope in the context of such a disabling and stigmatising illness. Until this time, patients were placed on wards from which they were often never discharged and ‘treatments’ were crude. Within 10 years, the ‘neuroleptic era’ was well under way and, for the first time since moral management, psychiatry was driven by a sense of therapeutic optimism. Reference Kerwin6 Concurrently, with Kuhn’s discovery of imipramine in 1957, a new science was emerging. The different psychological effects of some tricyclic structures (antidepressants) and others (antipsychotics) generated considerable excitement, and before long new theories suggesting a link between chemical structure and psychotropic effect were being considered. For example, whether a tricyclic chemical was an antidepressant or an antipsychotic was thought to be determined by the angle of the planes of the rings in the tricyclic molecule. This led to speculation that there were different brain mechanisms underpinning depression and schizophrenia. Reference Hippius7

These new developments and theories raised the possibility that advances in the laboratory could, perhaps, modify the brain processes underlying psychosis and depression. These were the beginnings of the new science of psychiatry. This was not the old ‘science’ of phenomenology allied with social exclusion and behavioural control in the asylum; this was a science that married the chemists’ laboratory with the psychiatric ward. It was simply a matter of time before more refined drugs would be developed that could selectively treat different mental states and illnesses. It is easy to miss an important fact here: this also marks the birth of a new industry. Reference Healy8

The rise of the ‘atypicals’

In the early 1960s, clozapine was synthesised. As a dibenzamine, it was thought that it would be an antidepressant. However, clozapine turned out to be an antipsychotic, but unlike other antipsychotics, there was no evidence of any extrapyramidal effects in animal studies. Reference Hippius7 As a first-line treatment for schizophrenia in high-income countries, clozapine came and went relatively quickly: its licence was withdrawn in Europe and North America in 1975 when eight patients in Finland died from agranulocytosis.

Clozapine’s mode of action was, nevertheless, different from other antipsychotics in that its clinical potency did not correlate with its ability to block dopamine D2 receptors, and the lower rate of extrapyramidal side-effects (EPS) suggested a different mode of antipsychotic action. This old drug, with its ‘new’ and ‘atypical’ mode of action, was re-introduced in the UK in 1990 (subject to strict blood monitoring in high-income countries) for the treatment of ‘treatment-resistant schizophrenia’ 4 – that is, schizophrenia not responding to the old, typical antipsychotics. Clozapine has continued to be a possible first-line treatment in low-income countries.

The concept of atypicality, associated with the revival of clozapine, gave hope that there would be a class of drugs with less severe side-effects, especially EPS and tardive dyskinesia. Atypicality also provided a powerful marketing tool for the industry. A number of new antipsychotics followed, each claiming to have a different mode of action: for example, risperidone blocking serotonin receptors as well as D2 receptors; Reference Janssen, Niemegeers, Awouters, Schellekens, Megens and Meert9 and each claiming greater efficacy and/or fewer side-effects. A new class of antipsychotics was born. Many psychiatrists, especially researchers closely connected to the drug industry, claimed that the emergence of the atypicals was a revolution in schizophrenia treatment and research comparable to the introduction of the original antipsychotic, chlorpromazine. Reference Kerwin6 Even the more sceptical thought that the advent of the atypicals was an important advance: patients could at least choose between being stiff and putting on weight. Indeed, it is a testament to the success of this marketing exercise that the National Institute for Health and Clinical Excellence (NICE) undertook a Technology Appraisal of the atypical antipsychotics in 2002. 10

Decline and fall

Doubts about the superiority and integrity of the atypicals emerged over 10 years ago. Geddes et al Reference Geddes, Freemantle, Harrison and Bebbington11 published a meta-regression suggesting that the apparent superiority of the atypicals was the result of not comparing like with like. Many of the trials (mainly sponsored by drug companies) compared moderate doses of an atypical with a higher dose of a potent typical such as haloperidol. The atypical drug thereby appeared to be more efficacious (e.g. fewer drop outs in an intention-to-treat analysis) and associated with comparatively lower rates of EPS. The authors estimated that if the dose of the typical antipsychotic was 12 mg or less of haloperidol (or equivalent), there was no difference in efficacy or overall tolerability. Although neither confirmed nor disproved by later meta-analyses, this view has considerable face validity, especially for trials completed within 8–10 weeks: a drug liable to produce significant early-onset side-effects, such as EPS and sedation, is likely to have a greater drop-out rate in the first weeks of treatment than one with later-onset side-effects such as obesity.

More recently, two effectiveness trials comparing atypicals and typicals (now called second-generation and first-generation antipsychotics (SGAs and FGAs)) have provided confirmation that there is no clear difference in effectiveness between these classes. Reference Lieberman, Stroup, McEvoy, Swartz, Rosenheck and Perkins12,Reference Jones, Barnes, Davies, Dunn, Lloyd and Hayhurst13 The CUtLASS trial Reference Jones, Barnes, Davies, Dunn, Lloyd and Hayhurst13 appeared to show that there is no difference in efficacy between the SGAs and FGAs, although the former cost more. And although the CATIE trial suggested olanzapine was more efficacious than others, Reference Lieberman, Stroup, McEvoy, Swartz, Rosenheck and Perkins12 this is not a ‘class’ effect. That there are no consistent differences between atypicals and typicals, SGAs and FGAs, has been confirmed in a recent meta-analysis of 150 trials of these drugs: in 95 of these trials the FGA comparator was a high-potency FGA – haloperidol – frequently at high doses. Reference Leucht, Corves, Arbter, Engel, Li and Davis14

In the recently updated NICE schizophrenia guideline we also found that there were no consistent differences between atypicals and typicals, SGAs and FGAs; there were no important differences between any of the antipsychotics in terms of clinical or cost-effectiveness (except for clozapine in treatment-resistant schizophrenia); the side-effects varied from drug to drug and were not determined by class; and all the antipsychotics were associated with potentially serious dose-related and other side-effects. 4 Although some of the newer drugs are associated with lower rates of EPS/tardive dyskinesia, they are also linked to different and equally severe side-effects such as diabetes, and some other newer drugs may have similar rates of EPS to the older drugs. From Girgis et al in this issue, it now seems unlikely that there are any longer-term benefits for using atypicals or SGAs in the first episode.

In creating successive new classes of antipsychotics over the years, the industry has helped develop a broader range of different drugs with different side-effect profiles and potencies, and possibly an increased chance of finding a drug to suit each of our patients. 4 But the price of doing this has been considerable – in 2003 the cost of antipsychotics in the USA equalled the cost of paying all their psychiatrists. The story of the atypicals and the SGAs is not the story of clinical discovery and progress; it is the story of fabricated classes, money and marketing. The study published today is a small but important piece of the jigsaw completing a picture that undermines any clinical or scientific confidence in these classes. With the industry reputation damaged by evidence of selective publishing and its deleterious effects, Reference Whittington, Kendall, Fonagy, Cottrell, Cotgrove and Boddington15,Reference Turner, Matthews, Linardatos, Tell and Rosenthal16 and the recent claims that trials of at least one of the new atypicals have been knowingly ‘buried’, Reference Spielmans and Parry2 it will take a great deal for psychiatrists to be persuaded that the next new discovery of a drug or a class will be anything more than a cynical tactic to generate profit. In the meantime, perhaps we can drop the atypical, second-generation, brand new and very expensive labels: they are all just plain antipsychotics.

Acknowledgements

I thank Clare Taylor, Tim Kember and Marie Halton for help in the preparation of this manuscript.

References

1 Girgis, RR, Phillips, MR, Li, X, Li, K, Jiang, H, Wu, C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year randomised clinical trial. Br J Psychiatry 2011; 199: 281–8.CrossRefGoogle ScholarPubMed
2 Spielmans, GI, Parry, PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethic Inq 2010; 7: 1329.CrossRefGoogle Scholar
3 Leucht, S Kissling, W, Davis, JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict. Psychol Med 2009; 39: 1591–602.CrossRefGoogle ScholarPubMed
4 National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (updated edition). British Psychological Society and Royal College of Psychiatrists, 2010.Google Scholar
5 Elkes, J, Elkes, C. Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. BMJ 1954; 2: 560–5.CrossRefGoogle ScholarPubMed
6 Kerwin, RW. Clozapine: back to the future for schizophrenia research. Lancet 1995; 345: 1063–4.CrossRefGoogle ScholarPubMed
7 Hippius, H. The history of clozapine. Psychopharmacology 1989; 99: S35.CrossRefGoogle ScholarPubMed
8 Healy, D. The Creation of Psychopharmacology. Harvard University Press, 2002.CrossRefGoogle Scholar
9 Janssen, PA, Niemegeers, CJ, Awouters, F, Schellekens, KH, Megens, AA, Meert, TF. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine D2 antagonistic properties. J Pharmacol Exp Ther 1988; 244: 685–93.Google Scholar
10 National Institute for Clinical Excellence. Guidance on Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal no. 43. NICE, 2002.Google Scholar
11 Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6.CrossRefGoogle ScholarPubMed
12 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.CrossRefGoogle ScholarPubMed
13 Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87.CrossRefGoogle Scholar
14 Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.CrossRefGoogle ScholarPubMed
15 Whittington, CJ, Kendall, T, Fonagy, P, Cottrell, D, Cotgrove, A, Boddington, E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–5.CrossRefGoogle ScholarPubMed
16 Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252–60.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 338
Total number of PDF views: 436 *
View data table for this chart

* Views captured on Cambridge Core between 02nd January 2018 - 10th April 2021. This data will be updated every 24 hours.

Access Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

The rise and fall of the atypical antipsychotics
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

The rise and fall of the atypical antipsychotics
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

The rise and fall of the atypical antipsychotics
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *